Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 3 | Mind Blowing Facts

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has significantly outperformed the Nasdaq Composite over the past year, and analysts remain strongly bullish on the stock’s prospects.

Barchart

EU approves new twice-yearly HIV prevention jab

The new treatment option comes amid a rise in HIV cases in parts of Europe.

Euronews

Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences

While all publicly traded enterprises aim for business success, achieving it can also ironically lead to valuation pressures. That's the tough lesson that pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) learned the hard way recently. Although the company delivered the goods for its latest financial disclosure, post-earnings digestion appears to have…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

This Overlooked Biotech Stock Is a Buy for Its Hidden Strengths

This biotech giant has hidden strengths that could unlock long-term upside.

Barchart

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR…

Benzinga

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.

Benzinga

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or…

Benzinga

EU regulator approves injectable HIV drug that experts say could help stop transmission

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV

The Independent UK

EU regulators greenlight twice-yearly HIV injection, hailed as medical breakthrough

The drug is expected to be formally approved by the European Commission this year.

Euronews

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit drop in its earnings.

Barchart

Millions will die in coming years if US funding for HIV programmes is not replaced, UN warns

US cuts could lead to four million AIDS-related deaths by 2029, according to UN officials.

Euronews

UN says if US funding for HIV programs is not replaced, millions more will die by 2029

A new U.N. AIDS agency report says the sudden withdrawal of U.S. funding has caused a “systemic shock” to the global effort against AIDS and HIV

The Independent UK

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need

FDA approval paves the way for the jab to roll out across the world. But with funding being slashed, will it get to the people who need it? Rachel Schraer reports

International Business Times UK

Marjorie Taylor Greene Buys Stocks Focusing on Tech, Energy, and a Biotech Firm That Recently Received FDA Approval for HIV Drug

US Congress member Marjorie Taylor Greene purchased shares of Adobe, Netflix, Snowflake, ServiceNow, NextEra Energy, and Gilead Sciences on 6th June.

The Independent UK

Groundbreaking twice-a-year HIV drug that could stop transmission approved

It's unclear how many people in the US and abroad will get access to the powerful new HIV prevention medication

International Business Times

US Approves Gilead's Twice-yearly Injection To Prevent HIV

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Here’s what to know about the twice-yearly preventative HIV shot

A twice-yearly drug called lenacapavir is now the longest-lasting type of PrEP

The Guardian - UK

‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers

As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’

The Independent UK

Millions of doses of ‘pandemic-ending’ HIV jab at risk over Trump’s aid cuts

INTERVIEW: The funding for 2 million people to receive the twice-yearly preventative treatment lenacapavir is ‘receding in the chaos’ of the US president’s decision, the doctor behind the trial of the drug tells Rachel Schraer

Inverse

'The Handmaid's Tale's Ending Brought The Show Back To Its Worst Habits

The series finally ended, but not without going back to its most annoying trope.

Barchart

Unusual Options Alert: The Smart Money is Piling Into Gilead Sciences (GILD)

While the new political paradigm might not be the most conducive environment for Gilead Sciences, positive sentiment is brewing for GILD stock.

The Independent UK

Handmaid’s Tale star breaks down episode 1’s shock reunion

Emotional scene is part of how the show will end

MarketBeat

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.